Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PN-235

Other · developed by Protagonist Therapeutics

Phase 1 Most advanced trial (none active)
PTGX Developer
1 Registered trials

What is PN-235?

PN-235 is an investigational agent with no further detail available in the source texts.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Active Drug
Drug type
Other
Developer
Protagonist Therapeutics, Inc. (PTGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04621630 Phase 1 Healthy Volunteers Completed PTGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Protagonist Therapeutics

Follow PTGX, the company behind PN-235

See PTGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.